• 2/15/2005
  • Phoenix, AZ
  • The Business Journal Phoenix

Zila Inc. has been granted an additional U.S. patent for its Zila Tolonium Chloride product, the company announced Tuesday. The patent covers certain compounds within the Zila Tolonium Chloride product and the use of these compounds in detecting a type of tissue which has been shown in testing to be a potential precursor to cancer.

Zila officials also said the company expects to receive patent protection in 15 European countries under an additional patent titled “Method and Prepackaged Swab for Epithelial Cancer Screening.” The European patents will cover the use of a prepackaged swab saturated with Zila Tolonium Chloride for performing routine screening procedures to detect cancer.

The use of Zila Tolonium Chloride as a screening agent to detect oral cancer has previously been approved by certain European regulatory agencies, and is currently pending regulatory review by the U.S. Food and Drug Administration.

Phoenix-based Zila Inc. develops and markets preventative health care technologies and products.